Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2023-04-19 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
关于公司向银行申请授信并提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Sailong Pharmaceutical Group Co., Ltd. regarding the company's application for bank credit and provision of guarantees. It includes details about the credit amount, guarantee limits, financial data, board meeting resolutions, and independent director opinions. The document is a formal disclosure of financing and guarantee activities, not a full financial report or earnings release. It does not contain comprehensive financial statements or detailed financial analysis but focuses on capital/financing updates and related approvals. The document length is about 3,046 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-04-19 Chinese
2022独立董事述职报告（张维）
Board/Management Information Classification · 95% confidence The document is titled as an independent director's annual performance report for the year 2022. It details the independent director's attendance at board and shareholder meetings, opinions on various company matters, committee participation, and efforts to protect investor rights. It does not contain financial statements or audit results but rather a narrative and opinion report on governance and oversight activities. This type of document fits best under Board/Management Information (MANG) as it relates to management and board activities and oversight rather than a financial report or audit report. The document length is 3064 characters, which is relatively short and focused on director duties and opinions rather than financial data or regulatory filings. Therefore, the classification is MANG with high confidence.
2023-04-19 Chinese
董事会审计委员会关于公司计提减值准备事项合理性的说明
Audit Report / Information Classification · 95% confidence The document is a statement from the Board Audit Committee regarding the reasonableness of impairment provisions made by the company for the year 2022. It references compliance with accounting standards and regulatory rules but does not contain full financial statements or detailed audit results. The document is a formal explanation or statement related to audit matters but is not a full audit report or annual report. Given its nature as a committee statement on an accounting matter, it fits best under Audit Report / Information (AR). The document length is short and focused on audit committee's opinion on impairment, not a full report or announcement of a report publication. FY 2022
2023-04-19 Chinese
2022独立董事述职报告（潘传云）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2022 by an independent director of the company. It details the director's attendance at board and shareholder meetings, opinions on various company matters, committee work, and efforts to protect investor rights. It is a narrative report on the director's activities and responsibilities rather than a financial report or announcement. The document length is 2731 characters, which is relatively short and focused on governance and director duties. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management activities and reports. It is not an Annual Report, Audit Report, or any other financial or regulatory filing. Therefore, the classification is MANG with high confidence.
2023-04-19 Chinese
监事会关于公司计提减值准备事项合理性的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the supervisory board (监事会) of a company regarding the reasonableness of impairment provisions made in the 2022 fiscal year. It references compliance with accounting standards and stock exchange listing rules, and confirms the appropriateness of the impairment provision. The document is very short (392 characters) and serves as an explanatory note or certification rather than a full financial report. It does not contain detailed financial data or comprehensive analysis. This fits best under Regulatory Filings (RNS), as it is a regulatory compliance statement and not a full audit report or annual report.
2023-04-19 Chinese
2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2022 Annual Report Summary" of 赛隆药业集团股份有限公司, indicating it is a summary of the full annual report. It contains detailed financial data for the year 2022, including revenue, net profit, assets, and shareholder information. The presence of comprehensive financial statements and business descriptions confirms it is a financial report for a full fiscal year. The document length is 6823 characters, which is sufficient to contain substantive financial data rather than just an announcement. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-04-19 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.